Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

MLA

Snijder, Berend, et al. “Image-Based Ex-Vivo Drug Screening for Patients with Aggressive Haematological Malignancies: Interim Results from a Single-Arm, Open-Label, Pilot Study.” The Lancet. Haematology, vol. 4, no. 12, Dec. 2017, pp. e595–606. EBSCOhost, https://doi.org/10.1016/S2352-3026(17)30208-9.

APA

Snijder, B., Vladimer, G. I., Krall, N., Miura, K., Schmolke, A.-S., Kornauth, C., Lopez de la Fuente, O., Choi, H.-S., van der Kouwe, E., Gültekin, S., Kazianka, L., Bigenzahn, J. W., Hoermann, G., Prutsch, N., Merkel, O., Ringler, A., Sabler, M., Jeryczynski, G., Mayerhoefer, M. E., … Superti-Furga, G. (2017). Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. The Lancet. Haematology, 4(12), e595–e606. https://doi.org/10.1016/S2352-3026(17)30208-9

Chicago

Snijder, Berend, Gregory I Vladimer, Nikolaus Krall, Katsuhiro Miura, Ann-Sofie Schmolke, Christoph Kornauth, Oscar Lopez de la Fuente, et al. 2017. “Image-Based Ex-Vivo Drug Screening for Patients with Aggressive Haematological Malignancies: Interim Results from a Single-Arm, Open-Label, Pilot Study.” The Lancet. Haematology 4 (12): e595–606. doi:10.1016/S2352-3026(17)30208-9.